Boston (1)

Adenocarcinoma Esophagus (1)

Esophageal Cancer (1)

Squamous Cell Esophagus Cancer (1)

Active, not recruiting (1)

phase 2 (1)

Dana-Farber Cancer Institute (1)

Merck Sharp & Dohme LLC (1)

pembrolizumab (1)

drug (1)

Other (1)

Interventional (1)

squamous cell esophagus cancer

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Active, not recruiting

Apr 7, 2022